Channels - Synergistic Antitumor Activity of HAT Inhibitor A485 and XPO1 Inhibitor KPT8602 in Multiple Myeloma :: FRELIP Discovery

Similar Items: Synergistic Antitumor Activity of HAT Inhibitor A485 and XPO1 Inhibitor KPT8602 in Multiple Myeloma

Quick Look
Correction to “Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma”
Quick Look
Potential of oncolytic viruses in the treatment of multiple myeloma
Quick Look
The Role of Genomics in the Development and Treatment of Multiple Myeloma: Understanding the Challenges and Opportunities
Quick Look
Defining High-Risk Disease Biology in Multiple Myeloma: A Narrative Review
Quick Look
Serum ATIC Expression as a Novel Diagnostic and Prognostic Biomarker in Multiple Myeloma Patients
Quick Look
IMMPACT-MM: Insights into Multiple Myeloma Patient Outcomes following Early-Line Cilta-cel Treatment
Quick Look
The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity
Quick Look
Prognostic Value of Next‐Generation Flow Cytometry Versus Dual‐Tracer PET/CT for Minimal Residual Disease Assessment in Multiple Myeloma
Quick Look
Re: predictive modeling of treatment-related thyroid dysfunction and prognostic implication in advanced nasopharyngeal carcinoma with PD-1 inhibitors
Quick Look
Burden of Disease, Treatment Patterns, and Healthcare Resource Utilization in Multiple Myeloma in the Middle East and North Africa Region: A Targeted Literature Review
Quick Look
Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity
Quick Look
RETRACTION: Tanshinone sensitized the antitumor effects of irradiation on laryngeal cancer via JNK pathway
Quick Look
The Ongoing Challenges of Managing Cytopenic Myelofibrosis in 2025: The Emergence of Non-JAK Inhibitor Therapies
Quick Look
Targeting Temozolomide‐Resistant Glioblastoma: Therapeutic Potential of Neuronal Nitric Oxide Synthase Inhibitor
Quick Look
Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab: A Panel Chart Review Study
Quick Look
In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses
Quick Look
Biomarker‐based long‐term safety and efficacy of PD‐1/PD‐L1 inhibitors combined with chemotherapy in advanced gastroesophageal carcinomas: A systematic review and meta‐analysis
Quick Look
Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases
Quick Look
Use of histone deacetylase inhibitors (HDACis) in pancreatic ductal adenocarcinoma (PDAC): A narrative review
Quick Look
Identification of Novel Small‐Molecule Inhibitors Targeting KDM5B and Evaluation of Their Antitumour Effects
Quick Look
Efficacy of CDK4/6 Inhibitor Plus Aromatase Inhibitor versus Fulvestrant in Chinese Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer
Quick Look
Health Disparities in Acute Myeloid Leukemia Patients Undergoing Treatment with Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2
Quick Look
RETRACTION: Delanzomib, a Novel Proteasome Inhibitor, Sensitizes Breast Cancer Cells to Doxorubicin‐Induced Apoptosis
Quick Look
Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL